Aldeyra Therapeutics Investors Eligible to Lead Securities Fraud Lawsuit

The Rosen Law Firm has filed a class action lawsuit on behalf of ALDX shareholders.

Apr. 1, 2026 at 12:26am

Got story updates? Submit your updates here. ›

The Rosen Law Firm, a global investor rights law firm, has announced that it has filed a class action lawsuit on behalf of purchasers of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between an unspecified date range. The lawsuit alleges securities fraud by the company.

Why it matters

This lawsuit represents an opportunity for Aldeyra Therapeutics investors to potentially recover losses and hold the company accountable for any alleged misconduct. Securities fraud lawsuits can have significant implications for public companies and their shareholders.

The details

The class action lawsuit alleges that Aldeyra Therapeutics made false and/or misleading statements and/or failed to disclose information pertinent to investors. The specific details of the alleged fraud have not been disclosed.

  • The lawsuit was filed on March 31, 2026.

The players

Rosen Law Firm

A global investor rights law firm that has filed the class action lawsuit on behalf of Aldeyra Therapeutics shareholders.

Aldeyra Therapeutics, Inc.

A biopharmaceutical company that is the defendant in the securities fraud lawsuit.

Got photos? Submit your photos here. ›

The takeaway

This lawsuit highlights the importance of transparency and accountability for public companies. Investors will be closely watching the developments in this case, which could have broader implications for the pharmaceutical industry.